BioDelivery Sciences stock has surged in the past month because investors realize the potential for Bunavail, its recently FDA approved treatment for opioid dependency, says the company's CEO Dr. Mark Sirgo. Sirgo says the ability of Bunavail to stick on the inside of the cheek, unlike products that need to be kept in place under the tongue until they dissolve, is evolutionary because it allows patients to talk, swallow and go about normal daily activities while the medication is being consistently absorbed. Sirgo says the product has peak sales potential of $250M and will hit the market in late 2014.


If you liked this article you might like

3 Biotech Stocks on Readers' Minds

Trump's FDA: A Friendlier Biotech Sheriff

2 Recovering Biotech Names With Room to Run

4 Undervalued Biotech Stocks

2 Oversold Biopharmas With Big 2017 Upsides